NASDAQ · Biotechnology

Cidara Therapeutics, Inc. (CDTX) Stock

$221.38 +0.00% NASDAQ: CDTX Healthcare

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs.

Valuation

MetricValue
Price$221.38
Market Cap$5.61B
P/E Ratio-25.99
P/B Ratio8.15
P/S Ratio5613.78
EPS (TTM)$-26.75
52-Week High$221.42
52-Week Low$15.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.30%
ROA-25.53%
ROCE-33.41%
Gross Margin-17600.00%
Operating Margin-17600.00%
Net Margin-17000.00%
Debt/Equity0.02
Current Ratio4.62

Annual Financials (USD)

Metric20202021202220232024
Revenue$12.0M$50.0M$64.0M$23.0M$1.0M
Operating Profit$-72.0M$-42.0M$-34.0M$-27.0M$-176.0M
Net Profit$-72.0M$-42.0M$-34.0M$-23.0M$-170.0M
EPS$-36.03$-16.19$-9.61$-5.25$-26.75
Op Margin-595.4%-85.2%-52.0%-116.2%-13811.9%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$60.0M$75.0M$47.0M$67.0M$215.0M
Total Liabilities$50.0M$54.0M$62.0M$75.0M$51.0M
Cash$36.0M$62.0M$33.0M$36.0M$190.0M
Borrowings$8.0M$5.0M$1.0M$5.0M$4.0M

Latest News

Veea Unveils Platform Enabling Cybersecure Sovereign Data Fabrics, Enterprise AI Grids for Physical AI MT Newswires · Jul 16, 2026 UK nationalises struggling British Steel AFP · Jul 16, 2026 Fed Chair Kevin Warsh Just Drove a Dagger Through Wall Street's Heart With This Telling 15-Word Statement on Inflation Motley Fool · Jul 16, 2026 Europe's energy use for cooling doubled in six years: Which countries use the most? Euronews · Jul 16, 2026 2 Stocks With Dividend Yields of At Least 5.9% That Have Also Raised Their Annual Dividends for At Least 50 Years Motley Fool · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-54.0M$-25.0M$-28.0M$-22.0M$-177.0M
Investing Cash Flow$0$0$0$-1.0M$0
Financing Cash Flow$0$0$-1.0M$0$0
Net Cash Flow$-17.0M$19.0M$-30.0M$3.0M$160.0M
Free Cash Flow$-55.0M$-25.0M$-29.0M$-23.0M$-177.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.88
EV / EBITDA-40.22
FCF Yield-1.84%
Quick Ratio4.62
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADPT $24.93 +5.64% -69.84 $3.99B 0.00%
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
BEAM $25.62 +2.19% -35.36 $2.64B 0.00%
CPRX $31.49 +0.00% 18.00 $3.85B 0.00%
IDYA $36.02 -2.05% -22.12 $3.42B 0.00%

About Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.

Cidara Therapeutics, Inc. is headquartered in US.

Cidara Therapeutics, Inc. (CDTX) stock trades at $221.38 with a market capitalization of $5.61B. The stock is valued at a price-to-earnings (P/E) ratio of -25.99, price-to-book of 8.15, price-to-sales of 5613.78. Over the past 52 weeks the stock has ranged between $15.22 and $221.42, and currently trades at its 52-week high.

On profitability, Cidara Therapeutics, Inc. generates a return on equity (ROE) of -37.30%, return on capital employed of -33.41%, an operating margin of -17600.00%, a net profit margin of -17000.00%.

Official website: www.cidara.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides